Angiogenesis, the formation of new blood vessels from pre-existing vasculature, and lymphangiogenesis, the development of new lymphatic vessels, are fundamental processes in cancer progression. Tumor-induced angiogenesis supplies nutrients and oxygen, facilitating primary tumor growth and providing a route for dissemination, while lymphangiogenesis is a key driver of metastatic spread via the lymphatic system. The dynamic crosstalk between tumor cells, endothelial cells, and other stromal components within the tumor microenvironment makes these processes critical therapeutic targets.
Utilizing organoid models for angiogenesis and lymphangiogenesis analysis offers a physiologically relevant and highly tractable system. Tumor organoids, often co-cultured with endothelial or lymphatic endothelial cells, self-organize into complex 3D structures that recapitulate the heterotypic interactions of the native tumor niche. This enables the direct observation and measurement of vessel sprouting, network formation, permeability, and the functional consequences of these processes in a controlled, human-derived context.
The organoid platform presents a superior model for studying tumor-associated vasculature by bridging the gap between simplistic 2D cultures and complex in vivo systems.
Physiological Relevance
Provides specific insights by avoiding species discrepancies inherent in rodent models, directly recapitulating tumor-vasculature interactions.
Direct Observability
Enables real-time and endpoint high-resolution imaging of vascular sprouting, network dynamics, and function within an intact 3D tumor model.
Structural and Functional Complexity
Supports the 3D self-organization of tumor and endothelial cells, enabling the formation of lumen-like structures and functional vessel networks.
Scalability & Reproducibility
Allows for precise manipulation of microenvironmental factors (e.g., hypoxia, growth factors) and is amenable to screening of therapeutic compounds.
Organoid models are actively employed in preclinical research to dissect mechanisms and identify modulators of tumor vasculature. Current applications in the field include:
| Organoid Model | Description |
| Breast Cancer Organoids | Investigating the correlation between VEGF-C expression and lymphatic vessel density to predict axillary lymph node metastasis. |
| Colorectal Cancer (CRC) Organoids | Modeling the interaction between tumor-derived factors and mesenteric endothelial cells to study vascular remodeling. |
| Glioblastoma Organoids | Assessing the highly abnormal, permeable vascular networks characteristic of brain tumors and testing VEGFR inhibitors. |
| Lung Cancer Organoids | Evaluating the role of hypoxia-inducible factors (HIF) in triggering rapid neo-angiogenesis within dense necrotic cores. |
| Melanoma Organoids | Focusing on vasculogenic mimicry, where tumor cells themselves form vessel-like structures to bypass traditional angiogenesis. |
Leveraging our proprietary bio-scaffolding technology and deep expertise in 3D cell biology, Alfa Cytology's team delivers end-to-end analysis that transforms raw biological data into therapeutic development insights. This encompasses robust model development, application of advanced quantitative readouts, and generation of data to accelerate your research in tumor vascular biology and metastasis.
Tailoring the developmental process to the specific requirements of the vascular study, a wide array of organoid models is engineered from diverse sources, including tumor tissues, PDX-derived tissues, and induced pluripotent stem cells (iPSCs). These models can be established as monocultures for baseline signaling studies or advanced into complex co-culture systems that integrate varied cell lineages to better reflect the heterogeneous nature of the vascular niche.
Harnessing the power of microfluidics and bio-fabrication, our advanced platforms provide a controlled environment to study vascular recruitment with microscopic precision.
Microfluidic Organ-on-a-Chip Platforms
These systems provide precise control over fluid flow, shear stress, and interstitial pressure. They are ideal for modeling perfusable vessel networks, studying intravasation/extravasation dynamics, and creating robust vascular barrier models for specialized drug delivery and permeability studies.
Complex Co-culture Systems
We integrate tumor organoids with isogenic or allogenic endothelial cells, pericytes, immune cells, and fibroblasts. This creates a more biomimetic TME to study the heterotypic paracrine signaling and cell-cell contact-mediated regulation that governs pathological vessel growth.
Employing precision 3D bioprinting to facilitate the reproducible formation of vascular channels and sacrificial scaffolds. This enables focused studies on organized angiogenesis, vessel maturation, and the spatial interplay between pre-patterned vasculature and invading tumor clusters.
Genetically Engineered Reporter Organoids
Utilizing gene editing, we generate organoids with fluorescent or luminescent tags in key genes (e.g., VEGFA, HIF1α) or endothelial-specific reporters (e.g., CD31-GFP) for real-time, non-invasive tracking of angiogenic signaling and endothelial cell behavior.
Focusing on the intricacies of the tumor microenvironment, our customized solutions delve deep into the molecular interplay between malignant cells and the vasculature.
Mechanistic Profiling
Integrates RNA sequencing of dissociated organoids to deconvolute endothelial cell states, tumor cell subpopulations, and their associated signaling pathways.
Functional Metabolic Coupling Analysis
Assesses metabolic exchange (e.g., glucose, lactate) between tumor and endothelial compartments using spatially resolved metabolomics or biosensors.
High-Content Spatiotemporal Mapping
Employs light-sheet/confocal microscopy and AI-driven analysis to quantify 3D network morphology, vessel permeability, and dynamic cell migration over time.
Therapeutic Efficacy & Resistance Modeling
Implements long-term treatment with anti-angiogenic agents (e.g., VEGF inhibitors) to model and study acquired resistance mechanisms within the organoid TME.
Paracrine Signaling Profiling
Quantifies the tumor organoid secretome via high-sensitivity multiplex assays to identify novel pro-angiogenic factors beyond the VEGF family.
Immune-Vascular Crosstalk
Investigating how vessel architecture regulates T-cell infiltration, a critical factor in the success of modern immune checkpoint therapies.
Synthesizing complex morphological data into quantitative insights is essential for characterizing the efficacy of vascular-targeted therapies. We provide a comprehensive analysis that encompasses molecular, morphological, and functional dimensions of vascular growth.
Alfa Cytology developed a vascularized lung cancer organoid model to recapitulate critical tumor-vasculature interactions. This was achieved by co-culturing lung cancer organoids (LCOs) with human blood vessel organoids in a defined 3D matrix. The model successfully demonstrated cancer cell migration and intimate association along the developing endothelial networks, mimicking early metastatic events. Comprehensive molecular and phenotypic characterization confirmed the induction of a pro-metastatic state within the tumor cells, marked by a clear shift in standard epithelial and mesenchymal marker expression, consistent with vasculature-induced epithelial-mesenchymal transition (EMT). Further analysis revealed the activation of key signaling pathways and a hypoxic response within the tumor compartment, underscoring the model's physiological relevance. These results validated our platform's capability to engineer complex, vascularized tumor microenvironments for investigating metastasis mechanisms and screening therapeutic interventions targeting tumor-endothelial crosstalk.
Fig.1 Immunofluorescence analysis of ZEB2, E-cadherin, and HIF1α expression compares the lung cancer organoid (LCO) model with vascularized LCO to assess the impact of the tumor-vascular microenvironment. Data are presented as mean ± SEM (n=5, *p < 0.05, **p < 0.01).
Alfa Cytology's integrated angiogenesis and lymphangiogenesis analysis service provides a powerful, human-relevant platform to unravel the role of the vasculature in cancer progression and therapy response. By combining sophisticated organoid models with multidisciplinary analysis, we deliver precise insights to advance your drug discovery and translational research programs. Contact us today to discuss customizing a project plan for your specific research needs.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.